Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochem Gokemeijer

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
The AAPS Journal|October 4, 2017
How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry PerspectiveJochem Gokemeijer, Vibha Jawa, Shibani Mitra-Kaushik
Analytical Biochemistry|July 27, 2013
Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodiesMaria D F S Barbosa, Jochem Gokemeijer, Aaron D Martin, et al.
Frontiers in Immunology|July 23, 2020
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020Vibha Jawa, Frances Terry, Jochem Gokemeijer, et al.
Chemistry & Biology|May 25, 2006
Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitroElena V Getmanova, Yan Chen, Laird Bloom, et al.
Molecular Therapy. Advances|June 30, 2026
Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kineticsXianghong Liu, Hongxiang Hu, Yanshan Dai, et al.
The AAPS Journal|May 20, 2026
HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with IpilimumabSurendran Rajendran, Andres H Gutierrez, Ming-Shan Chien, et al.
Journal of Pharmaceutical Sciences|May 20, 2024
Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular ProductJohanna Mora, Daron Forman, Jennifer Hu, et al.
Analytical and Bioanalytical Chemistry|December 2, 2011
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodiesShujie J Wang, Steven T Wu, Jochem Gokemeijer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectinAnthony W Tolcher, Christopher J Sweeney, Kyri Papadopoulos, et al.
Clinical Pharmacology and Therapeutics|July 2, 2023
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry PerspectiveHardik Mody, Ken Ogasawara, Xu Zhu, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The AAPS Journal|October 4, 2017
How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry PerspectiveJochem Gokemeijer, Vibha Jawa, Shibani Mitra-Kaushik
Analytical Biochemistry|July 27, 2013
Altering drug tolerance of surface plasmon resonance assays for the detection of anti-drug antibodiesMaria D F S Barbosa, Jochem Gokemeijer, Aaron D Martin, et al.
Frontiers in Immunology|July 23, 2020
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020Vibha Jawa, Frances Terry, Jochem Gokemeijer, et al.
Chemistry & Biology|May 25, 2006
Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitroElena V Getmanova, Yan Chen, Laird Bloom, et al.
Molecular Therapy. Advances|June 30, 2026
Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kineticsXianghong Liu, Hongxiang Hu, Yanshan Dai, et al.
The AAPS Journal|May 20, 2026
HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with IpilimumabSurendran Rajendran, Andres H Gutierrez, Ming-Shan Chien, et al.
Journal of Pharmaceutical Sciences|May 20, 2024
Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular ProductJohanna Mora, Daron Forman, Jennifer Hu, et al.
Analytical and Bioanalytical Chemistry|December 2, 2011
Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodiesShujie J Wang, Steven T Wu, Jochem Gokemeijer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectinAnthony W Tolcher, Christopher J Sweeney, Kyri Papadopoulos, et al.
Clinical Pharmacology and Therapeutics|July 2, 2023
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry PerspectiveHardik Mody, Ken Ogasawara, Xu Zhu, et al.
Pageof 2